six
poliovirusneutr
fab
recov
combinatori
fab
phage
display
librari
construct
bone
marrowderiv
lymphocyt
immun
chimpanze
chimer
chimpanzeehuman
fulllength
igg
hereinaft
call
monoclon
antibodi
mab
gener
combin
chimpanze
igg
light
chain
variabl
domain
heavi
chain
human
constant
fc
region
six
mab
neutral
vaccin
strain
virul
strain
polioviru
five
mab
serotyp
specif
one
mab
crossneutr
serotyp
epitop
map
perform
select
sequenc
antibodyresist
viral
variant
indic
crossneutr
mab
bound
antigen
site
therebi
cover
canyon
region
contain
receptorbind
site
anoth
serotyp
mab
recogn
region
locat
antigen
site
includ
part
capsid
protein
serotyp
antibodi
recogn
antigen
site
escap
mutant
serotyp
mab
could
gener
administr
serotyp
mab
transgen
mice
suscept
polioviru
dose
gmous
complet
protect
paralysi
challeng
lethal
dose
wildtyp
polioviru
moreov
mab
inject
h
viru
infect
provid
signific
protect
mab
describ
could
test
clinic
trial
determin
whether
might
use
treatment
immunocompromis
chronic
viru
excretor
emerg
protect
contact
paralyt
poliomyel
case
poliomyel
infecti
neurolog
diseas
caus
poliovirus
three
distinct
serolog
type
two
highli
effect
vaccin
one
prepar
formalininactiv
virul
viru
anoth
live
attenu
strain
administ
oral
develop
worldwid
use
result
almost
complet
erad
diseas
countri
remain
endem
thousand
paralyt
case
annual
dramat
success
diminish
interest
develop
new
protect
measur
complet
erad
poliomyel
perceiv
close
howev
origin
erad
target
date
miss
least
year
due
varieti
scientif
logist
polit
obstacl
therefor
recent
year
setback
global
effort
erad
poliomyel
newli
recogn
challeng
final
phase
whocoordin
campaign
need
prevent
reemerg
poliomyel
posterad
period
led
renew
effort
develop
effici
vaccin
new
strategi
use
tool
protect
poliomyel
includ
licensur
potent
monoval
bival
oral
polio
vaccin
mopv
bopv
respect
develop
new
gener
inactiv
polioviru
vaccin
use
posterad
period
develop
drug
effect
polioviru
use
opv
associ
small
risk
vaccineassoci
paralyt
poliomyel
vapp
vaccin
recipi
immedi
contact
also
led
emerg
circul
vaccinederiv
poliovirus
cvdpv
immunodeficiencyassoci
vdpv
ivdpv
vdpv
first
type
caus
outbreak
paralyt
poliomyel
inadequ
immun
commun
indistinguish
wild
poliovirus
pathogen
properti
ivdpv
emerg
opvvaccin
individu
primari
bcell
immunodefici
establish
chronic
infect
excret
environ
sever
year
besid
immedi
danger
chronic
carrier
patient
eventu
becom
paralyz
continu
evolv
polioviru
presenc
chronic
excretor
pose
seriou
challeng
polio
erad
campaign
provid
ampl
sourc
virul
poliovirus
environ
make
imposs
halt
immun
poliomyel
therefor
find
effect
treatment
patient
import
public
health
object
us
nation
research
council
recommend
develop
least
two
polio
antivir
drug
treat
chronic
infect
individu
assist
manag
outbreak
posterad
period
earli
work
hammond
al
show
gamma
globulin
effect
prevent
poliomyel
review
refer
therefor
passiv
immunotherapi
could
anoth
way
treat
chronic
excretor
even
though
prior
attempt
use
intraven
immunoglobulin
ivig
breast
milk
unsuccess
reason
think
higher
dose
antipolioviru
antibodi
could
result
complet
clearanc
polioviru
chronic
infect
individu
commun
report
develop
hybrid
chimpanzeehuman
antipolioviru
immunoglobulin
could
use
clinic
trial
assess
effect
treatment
chronic
polioviru
excretor
well
postexposur
emerg
prophylaxi
diseas
prevent
reemerg
poliomyel
posterad
period
immun
chimpanze
polioviru
vaccin
construct
combinatori
fab
antibodi
librari
two
chimpanze
immun
oral
three
serotyp
oral
polio
vaccin
opv
glaxosmithklin
twice
interv
boost
intramuscularli
inactiv
polio
vaccin
ipv
glaxosmithklin
month
year
second
immun
bone
marrow
aspir
chimpanze
day
last
immun
bone
marrowderiv
lymphocyt
prepar
centrifug
ficollpaqu
gradient
use
construct
combinatori
fab
phage
display
librari
describ
previous
fab
phage
display
librari
contain
heavi
chain
light
chain
divers
construct
chimpanze
protocol
approv
institut
anim
care
use
committe
anim
hous
facil
accredit
aaalac
pan
phage
librari
select
poliovirusspecif
fab
phage
produc
librari
describ
previous
pan
affin
bind
separ
serotyp
sabin
strain
polioviru
enzymelink
immunosorb
assay
elisa
plate
cycl
pan
l
opv
virus
use
immun
pfuml
phosphatebuff
salin
pb
use
coat
well
elisa
plate
specif
phage
select
incub
phage
coat
viru
poliovirusspecif
fab
clone
enrich
three
cycl
pan
three
serotyp
pan
singl
phagefab
clone
cultur
plate
phage
product
result
phage
screen
specif
bind
polioviru
phage
elisa
clone
bound
viru
bovin
serum
albumin
bsa
score
poliovirusspecif
clone
dna
sequenc
analysi
specif
fab
gene
code
variabl
region
heavi
v
h
light
v
l
chain
poliovirusspecif
fab
sequenc
fab
distinct
v
h
v
l
sequenc
regard
separ
fab
clone
presum
immunoglobulin
famili
usag
germ
line
origin
somat
mutat
identifi
comparison
deposit
imgt
sequenc
databas
http
wwwimgtorg
product
fab
igg
describ
previous
histidinetag
fab
express
escherichia
coli
affinitypurifi
nickel
column
igg
express
transient
transfect
mammalian
cell
purifi
protein
column
fab
igg
purifi
cationexchang
sulfopropyl
sp
column
ge
healthcar
puriti
fab
igg
evalu
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
protein
concentr
determin
optic
densiti
measur
nm
od
assumpt
correspond
mgml
measur
neutral
activ
specif
fab
purifi
fab
use
plaqu
reduct
neutral
test
prnt
determin
neutral
activ
three
polio
serotyp
typic
approxim
pfu
sabin
polioviru
l
serumfre
dulbecco
modifi
eagl
medium
dmem
mix
volum
serial
dilut
fab
virusfab
mixtur
incub
room
temperatur
h
ad
confluent
hela
cell
plate
duplic
h
incub
room
temperatur
overlay
dmem
contain
fetal
bovin
serum
fb
methyl
cellulos
ad
plate
incub
co
incub
h
plaqu
visual
stain
crystal
violet
min
elisa
well
elisa
plate
coat
l
polioviru
opv
concentr
pfuml
follow
treatment
milk
pb
wash
plate
incub
serial
antipolioviru
igg
h
room
temperatur
wash
plate
incub
h
horseradish
peroxidaseconjug
antibodi
human
fc
color
develop
ad
tetramethylbenzidin
reagent
kpl
gaithersburg
md
develop
stop
h
min
od
read
elisa
plate
reader
data
plot
doserespons
curv
gener
prism
softwar
graphpad
softwar
inc
san
diego
ca
block
elisa
test
base
materi
reagent
develop
previou
studi
amount
antigen
unitsml
polioviru
captur
elisa
plate
coat
purifi
rabbit
polyclon
serotypespecif
igg
gml
well
contain
captur
antigen
incub
serial
dilut
monoclon
antibodi
mab
polyclon
serum
block
reaction
control
well
treat
normal
rabbit
serum
well
antigen
serv
background
control
antipolioviru
antibodi
react
respect
antigen
site
block
subsequ
reaction
biotinconjug
polyclon
antipolio
igg
gml
next
extravidinperoxidas
conjug
dilut
sigma
ad
reaction
bound
peroxidas
tetramethylbenzidin
substrat
tmb
sigma
result
develop
color
reaction
addit
stop
reagent
sigma
plate
scan
nm
od
background
well
contain
antigen
correspond
block
activ
od
antigencontain
well
incub
normal
rabbit
serum
correspond
block
activ
percentag
block
activ
specif
mab
serum
particular
antigen
calcul
differ
averag
od
block
nonblock
well
contain
antigen
final
result
block
reactiv
calcul
follow
formula
block
activ
averag
od
well
contain
normal
rabbit
serum
averag
od
well
contain
test
serum
averag
od
well
normal
rabbit
serum
averag
od
background
well
antigen
titer
defin
serum
dilut
produc
block
graphic
linear
sshape
block
elisa
titrat
curv
perform
plot
logarithm
block
activ
block
activ
logarithm
dilut
polyclon
rabbit
antisera
obtain
immun
femal
rabbit
sabin
strain
polioviru
describ
elsewher
microneutr
test
poliovirusneutr
antibodi
titer
determin
microneutr
test
accord
recommend
modif
mab
sampl
dilut
gml
mainten
medium
dmem
supplement
fb
antibioticantimycot
solut
invitrogen
carlsbad
ca
steril
filtrat
spinx
column
corn
corn
ny
twofold
serial
dilut
antibodi
start
gml
incub
quadrupl
h
tissu
cultur
infecti
dose
tcid
respect
polioviru
strain
atmospher
co
incub
cell
ad
well
plate
incub
day
co
evalu
microscop
neutral
antibodi
titer
calcul
use
formula
gener
escap
mutant
antibodi
dilut
approxim
gml
mainten
medium
steril
filtrat
spinx
column
four
dilut
antibodi
start
gml
incub
h
room
temperatur
approxim
tcid
polioviru
follow
incub
h
allow
neutral
suscept
viru
monolay
cell
inocul
viru
incub
co
cytopath
effect
cpe
develop
viruscontain
cell
suspens
subject
three
freezethaw
cycl
releas
intracellular
viru
clarifi
centrifug
viral
titer
determin
microtitr
assay
plaqu
purif
monolay
plate
inocul
serial
dilut
mutant
virus
tcid
ml
incub
h
room
temperatur
next
medium
replac
ml
modifi
eagl
medium
mem
agaros
overlay
contain
fb
invitrogen
plaqu
pick
h
incub
co
transfer
plate
confluent
monolay
incub
cpe
develop
viruscontain
cell
suspens
subject
three
freezethaw
cycl
releas
intracellular
viru
clarifi
centrifug
nucleotid
sequenc
viral
rna
isol
viruscontain
medium
use
qiaamp
viral
rna
minikit
qiagen
valencia
ca
rna
amplifi
revers
transcript
rt
pcr
use
qiagen
onestep
rtpcr
kit
qiagen
typespecif
primer
allow
amplif
entir
capsid
region
polioviru
reaction
mixtur
assembl
accord
manvol
chimpanzeehuman
antipolioviru
monoclon
antibodi
ufactur
recommend
revers
transcript
step
min
follow
min
incub
cycl
pcr
follow
denatur
step
min
primer
anneal
step
min
elong
step
result
rtpcr
confirm
agaros
gel
electrophoresi
amplifi
dna
purifi
use
qiaquick
pcr
purif
kit
qiagen
rna
isol
pcr
purif
step
perform
qiacub
autom
station
qiagen
purifi
pcr
product
sequenc
regular
sanger
method
typespecif
primer
cover
strand
dna
space
bp
apart
four
primer
use
sequenc
strand
dna
pcr
product
overlap
read
assembl
align
refer
sabin
sequenc
use
macintosh
macvector
program
packag
macvector
inc
cari
nc
use
detect
mutat
rel
sequenc
parent
strain
tg
mous
challeng
test
transgen
mice
obtain
central
institut
experiment
anim
tokyo
japan
mainten
contain
transport
mice
perform
accord
recommend
memorandum
transgen
mice
suscept
human
virus
experi
use
mice
perform
accord
us
guid
care
use
laboratori
anim
protect
experi
group
mice
male
femal
inject
intraven
iv
g
g
g
antibodi
ml
pb
control
one
group
anim
inject
iv
ml
pb
h
anim
challeng
intramuscularli
im
time
paralyt
dose
pd
wildtyp
polioviru
mahoney
strain
mice
observ
sign
paresisparalysi
day
postexposur
treatment
experi
group
mice
equal
number
male
femal
challeng
im
pd
mahoney
viru
h
later
inject
iv
g
g
antibodi
control
group
receiv
pb
instead
anim
observ
clinic
sign
week
phage
fab
display
librari
construct
bone
marrowderiv
lymphocyt
chimpanze
immun
polioviru
pan
three
cycl
poliovirus
serotyp
phagefab
clone
specif
three
serotyp
identifi
phage
elisa
sequenc
analysi
variabl
domain
heavi
v
h
light
v
l
chain
show
nine
clone
specif
serotyp
three
clone
specif
serotyp
seven
clone
specif
serotyp
recov
posit
clone
subsequ
convert
produc
solubl
fab
solubl
fab
confirm
specif
bind
pan
antigen
tabl
measur
neutral
activ
prnt
show
fab
fab
fab
neutral
sabin
polioviru
serotyp
respect
tabl
six
fab
clone
rel
higher
neutral
activ
therefor
select
convers
fulllength
igg
refer
hereinaft
mab
character
closest
human
vgene
germ
line
usag
possibl
somat
mutat
six
poliovirusneutr
mab
identifi
conduct
sequenc
similar
search
known
human
ig
gene
compil
imgt
databas
http
wwwimgtorg
analysi
show
famili
heavi
chain
gene
famili
kappa
chain
gene
overrepres
v
h
v
l
gene
highli
mutat
sinc
ident
v
h
v
l
comparison
germ
line
vgene
observ
tabl
suggest
signific
affin
matur
may
taken
place
specif
poliovirusneutr
mab
six
poliovirusneutr
mab
examin
elisa
bind
polioviru
serotyp
virion
immobil
plate
mab
recov
pan
vitro
neutral
activ
c
v
h
v
l
gene
region
use
calcul
percentag
nucleic
acid
ident
mutat
first
bp
exclud
sinc
mutat
could
introduc
pcr
primer
c
insert
region
addit
ident
type
polioviru
one
react
sabin
viru
fig
interestingli
mab
exhibit
dual
specif
react
sabin
sabin
poliovirus
fig
mab
select
pan
type
polioviru
react
well
sabin
polioviru
fig
mab
recov
pan
type
polioviru
react
well
sabin
fig
sabin
viru
also
react
weakli
type
mab
direct
elisa
may
necessarili
reflect
function
interact
lead
neutral
detect
rel
weak
bind
antibodi
antigen
previous
show
block
elisa
procedur
mab
use
compet
neutral
polyclon
serum
much
predict
function
interact
result
correl
well
neutral
test
result
result
tabl
show
inde
weak
interact
type
antibodi
sabin
polioviru
detect
previou
experi
occur
set
howev
type
antibodi
strongli
react
type
polioviru
suggest
may
neutral
two
serotyp
polioviru
anoth
experi
block
elisa
perform
variou
concentr
mab
use
attenu
sabin
wild
poliovirus
antigen
fig
except
type
mab
react
equal
well
sabin
wild
saukett
strain
mab
react
better
sabin
strain
wild
strain
serotyp
differ
especi
pronounc
type
antibodi
practic
block
wild
polioviru
tabl
show
mab
select
serotyp
effect
neutral
homotyp
virus
addit
consist
elisa
data
mab
neutral
type
type
poliovirus
mab
neutral
sabin
wild
strain
polioviru
other
exhibit
signific
bia
sabin
strain
neutral
titer
mab
test
wild
time
lower
sabin
strain
mab
lower
neutral
activ
wildtyp
sabin
strain
crossneutr
differ
serotyp
polioviru
rel
unknown
phenomenon
difficult
imposs
studi
human
matern
antibodi
present
newborn
children
also
routin
use
vaccin
trival
therefor
assess
whether
rabbit
antisera
rais
immun
purifi
monoval
poliovirus
would
demonstr
evid
crossneutr
data
tabl
show
littl
cross
neutral
among
serotyp
suggest
polyspecif
antibodi
repres
major
neutral
antibodi
rabbit
polyclon
antisera
local
neutral
epitop
identifi
epitop
primat
mab
bind
select
escap
mutant
treat
sabin
poliovirus
antibodi
plaqu
purifi
resist
strain
sequenc
rna
identifi
mutat
render
strain
resist
neutral
abl
gener
escap
mutant
antibodi
specif
type
fail
obtain
resist
variant
type
polioviru
mutant
contain
sever
mutat
frequent
g
e
locat
close
antigen
site
mutat
make
viru
resist
antibodi
k
r
e
vicin
first
mutat
closer
antigen
site
also
compos
fig
differ
mutat
amino
acid
site
appear
produc
differ
effect
block
elisa
reactiv
strain
instanc
block
activ
antibodi
measur
g
viru
stronger
measur
e
mean
standard
deviat
respect
resist
strain
gener
respons
dualreact
antibodi
also
contain
unusu
pattern
mutat
clone
isol
sabin
strain
contain
v
e
mutat
clone
isol
sabin
strain
contain
g
mutat
fig
sabin
escap
clone
also
contain
may
necessari
resist
mutat
lead
direct
revers
mahoney
amino
acid
mahoney
viru
sensit
mutat
v
e
previous
identifi
part
antigen
site
locat
close
virion
surfac
close
canyon
surround
axi
symmetri
contrast
mutat
g
make
sabin
strain
resist
antibodi
locat
opposit
side
canyon
part
antigen
site
thu
appear
bind
virion
interact
side
canyon
bottom
bind
site
cellular
receptor
locat
escap
mutant
gener
respons
type
antibodi
contain
mutat
r
c
l
respect
locat
bc
loop
protein
previous
defin
epitop
preand
postexposur
protect
mice
infect
virul
polioviru
determin
whether
mab
protect
poliomyel
vivo
intraven
inocul
transgen
mice
express
human
polioviru
receptor
variou
dose
mab
challeng
intramuscularli
paralyt
dose
pd
wild
polioviru
mahoney
strain
tabl
show
g
mab
protect
mice
g
protect
averag
neutral
titer
serum
group
respect
consist
common
notion
neutral
titer
protect
polio
protect
effect
mab
quit
predict
consid
high
potenc
antibodi
also
import
determin
whether
antibodi
could
use
prevent
paralyt
diseas
administ
exposur
viru
result
shown
tabl
demonstr
mice
surviv
challeng
dose
treat
g
antibodi
either
h
infect
clear
protect
effect
even
though
mice
surviv
observ
suggest
antibodi
could
use
emerg
prophylaxi
nonimmun
individu
expos
polioviru
describ
isol
chimer
chimpanzeehuman
antipolioviru
antibodi
combin
hyperimmun
chimpanze
phage
fab
display
librari
technolog
method
previous
use
isol
human
mab
varieti
viral
bacteri
pathogen
compar
method
base
human
hybridoma
technolog
bcell
immort
epsteinbarr
viru
method
describ
commun
advantag
produc
clone
immunoglobulin
gene
could
use
directli
product
antibodi
express
vitro
well
genet
manipul
could
improv
therapeut
properti
antigen
structur
poliovirus
extens
studi
past
three
distinct
serotyp
polioviru
defin
inabl
crossneutr
sera
rais
two
serotyp
elucid
molecular
structur
polioviru
introduct
mab
technolog
allow
epitop
mous
mab
map
surfac
polio
virion
mutat
render
polioviru
resist
mab
identifi
epitop
antibodi
interact
epitop
differ
mab
cluster
sever
structur
region
antigen
site
surfac
polio
virion
studi
three
serotyp
polioviru
identifi
three
four
antigen
site
antigen
site
compos
socal
bc
loop
adjac
region
within
three
antigen
site
compos
combin
differ
capsid
protein
case
belong
adjac
capsom
polioviru
epitop
believ
conform
sensit
disrupt
virion
structur
littl
known
human
antipolio
antibodi
circumstanti
evid
repertoir
may
differ
mice
mab
chimpanze
closest
rel
human
describ
paper
support
notion
one
interest
observ
dual
specif
antibodi
bind
neutral
type
type
poliovirus
result
crossneutr
experi
hyperimmun
rabbit
antisera
suggest
dualspecif
antibodi
may
exist
rabbit
immunoglobulin
repertoir
howev
indic
crossneutr
antibodi
may
uncommon
human
antisera
uhlig
dernick
isol
four
immort
clone
human
b
cell
produc
neutral
antipolioviru
antibodi
one
antibodi
neutral
type
poliovirus
anoth
neutral
three
serotyp
albeit
lower
potenc
type
anoth
studi
mous
monoclon
antibodi
shown
neutral
type
type
polioviru
epitop
antibodi
map
amino
acid
residu
far
bind
site
therefor
dualreact
antibodi
may
repres
class
crossneutr
antibodi
role
underestim
studi
human
antibodi
need
assess
magnitud
phenomenon
method
describ
commun
well
suit
target
screen
crossneutr
antibodi
phage
display
pan
fab
fragment
induc
one
serotyp
antigen
anoth
serotyp
exist
crossneutr
antibodi
goe
common
belief
underli
classif
poliovirus
three
serotyp
classif
base
neutral
test
perform
hyperimmun
anim
sera
may
contain
crossneutr
antibodi
difficult
studi
question
human
either
epidemiolog
experiment
crossreact
antibodi
monkey
sera
reveal
complement
fixat
test
circumstanti
evid
base
comparison
ipvinduc
seroconvers
complet
immunolog
children
children
expos
heterolog
wild
poliovirus
suggest
may
crossserotyp
prime
effect
success
isol
escap
mutant
type
type
polioviru
unabl
isol
type
antibodyresist
strain
reason
unknown
may
relat
extrem
high
potenc
type
antibodi
inabl
disrupt
virusantibodi
interact
one
mutat
low
viabil
result
escap
mutant
epitop
bind
mab
describ
map
antigen
site
previous
identifi
mous
antibodi
other
may
differ
bind
mechan
instanc
dual
type
antibodi
appear
bind
antigen
site
thu
fill
canyon
virion
surfac
receptorbind
site
locat
interestingli
one
antibodyresist
mutat
gener
respons
treatment
g
previous
shown
reduc
bind
cellular
receptor
therefor
reason
suggest
antibodi
prevent
viru
bind
cellular
receptor
comparison
amino
acid
sequenc
threedimension
structur
relev
part
sabin
sabin
capsid
protein
show
similar
amino
acid
differ
region
involv
chemic
similar
amino
acid
provid
explan
dual
reactiv
antibodi
anoth
antibodi
bind
space
antigen
site
therefor
part
virion
immunolog
import
mice
chimpanze
appear
differ
studi
nativ
human
antibodi
polioviru
need
better
defin
antigen
site
util
passiv
immunotherapi
prevent
poliomyel
well
document
past
previou
attempt
use
intraven
immunoglobulin
breast
milk
unsuccess
even
though
signific
temporari
decreas
shed
observ
patient
treat
breast
milk
failur
complet
stop
shed
may
due
insuffici
level
antipolioviru
antibodi
ivig
breast
milk
avail
highli
potent
humanlik
antibodi
polioviru
open
possibl
cure
chronic
infect
individu
polioviru
infect
therebi
stop
shed
viru
environ
addit
recombin
chimpanzeehuman
antibodi
describ
could
boost
neutral
titer
extrem
high
level
therebi
resolv
chronic
infect
efficaci
monoclon
antibodi
must
evalu
clinic
trial
plan
transgen
mous
data
present
suggest
antibodi
protect
poliomyel
given
prior
infect
also
exposur
polioviru
mean
antibodi
stop
develop
infecti
process
even
start
rais
possibl
use
emerg
prophylaxi
contact
paralyt
polio
case
prevent
spread
polioviru
reemerg
appar
erad
circumst
emerg
vaccin
perform
stop
outbreak
ad
treatment
antipolioviru
antibodi
intervent
result
immedi
protect
individu
involv
allow
longerterm
effect
vaccin
develop
conclus
find
present
commun
open
possibl
better
character
human
immun
respons
polioviru
produc
therapeut
reagent
use
polio
erad
transit
poliofre
world
